Skip to main content
Premium Trial:

Request an Annual Quote

Advion, Bruker Ink Mass Spec Co-Marketing Deal

NEW YORK (GenomeWeb News) – Advion BioSystems announced today that it has signed a co-marketing agreement with Bruker Daltonik to sell the firm’s TriVersa NanoMate nanoelectrospray source with Bruker’s mass spectrometers.
Under the agreement, the firms have exchanged instruments for applications development and product demonstration. In addition, the companies will co-promote their products at industry tradeshows and conferences, Ithaca, NY-based Advion said in a statement.
Advion said that the TriVersa NanoMate combines the benefits of liquid chromatography, fraction collection, and chip-based infusion in a single system.
“Bruker’s market position in the life sciences allows Advion’s customers more flexibility to use its equipment as well as opening greater market potential for future sales in proteomic, biomarker, and metabolism applications,” said Jack Henion, Advion’s chief scientific officer.
Further terms of the alliance were not disclosed.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.